Клинические и экономические перспективы применения экстрамелкодисперсных аэрозольных ингаляторов

1. Bisgaard H, O'Callaghan C, Smaldone GC. Drug Delivery to the Lung. RC Press, 2001.
2. Usmani OS, Biddiscombe MF, Barnes PJ. Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size. Am J Respir Crit Care Med 2005; 172 (12): 1497–504.
3. Atkins PJ. Dry Powder Inhalers: An Overview. Respir Care 2005; 50 (10): 1304–12.
4. Granlund KM, Asking L, Lindblad T et al. An in-vitro comparison of budesonide/formoterol and fluticasone/salmeterol in dry powder inhalers. Eur Respir J 2000; 16 (Suppl. 31): 455s.
5. Yang TT, Li S, Wyka B, Kenyon D. Drug delivery performance of the mometasone furoate dry powder inhaler. J Aerosol Med 2001; 14 (4): 487–94.
6. O’Callaghan C, Wright P, Bisgaard H. The metered-dose inhaler. Drug delivery to the lung. New York: Marcel Dekker, 2002: 337–70.
7. McCallister JW, Moore WC. Hydrofluoroalkane preparations of fluticasone propionate. Expert Rev Respir Med 2008; 2 (4): 433–42.
8. Escribano A, Tutuncu A, Löhr I et al. Clinical comparability between the CFC and HFA budesonide pressurized metered-dose inhalers in paediatric patients with asthma: a randomised controlled trial. Curr Med Res Opin 2006; 22: 1085–92.
9. Busse WW, Brazinsky S, Jacobson K et al. Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J Allergy Clin Immunol 1999; 104: 1215–22.
10. Dolovich M. New delivery systems and propellants. Can Respir J 1999; 6 (3): 290–5.
11. Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J 1998; 12 (6): 1346–53.
12. Ganderton D, Lewis D, Davies R et al. Modulite: a means of designing the aerosols generated by pressurized metered dose inhalers. Respir Med 2002; 96 (Suppl. D): S3–8.
13. De Backer W, Devolder A, Poli G et al. Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. J Aerosol Med Pulm Drug Deliv 2010; 23 (3): 137–48.
14. Cripps A, Riebe M, Schulze M, Woodhouse R. Pharmaceutical transition to non-CFC pressurized metered dose inhalers. Respir Med 2000; 94 (Suppl. B): S3–9.
15. Johnson M. Fluticasone Propionate: Pharmacokinetic and Pharmacodynamic Implications of Different Aerosol Delivery Systems. RDD VI 1998; 1: p. 61–70.
16. Newman S, Salmon A, Nave R, Drollmann A. High lung deposition of 99mTc-labeled ciclesonide administered via HFA-MDI to patients with asthma. Respir Med 2006; 100 (3): 375–84.
17. Thorsson L, Edsbäcker S, Conradson TB. Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI. Eur Respir J 1994; 7 (10): 1839–44.
18. Mitchell JP, Nagel MW, Archer AD. Size analysis of a pressurized metered dose inhaler-delivered suspension formulation by the API Aerosizer time-of-flight aerodynamic particle size analyzer. J Aerosol Med 1999; 12 (4): 255–64.
19. Hochrainer D, Hölz H, Kreher C et al. Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers. J Aerosol Med 2005; 18 (3): 273–82.
20. Cerasoli F Jr. Developing the ideal inhaled corticosteroid. Chest 2006; 130 (Suppl. 1): 54S–64S.
21. Nave R, McCracken N. Metabolism of ciclesonide in the upper and lower airways: review of available data. J Asthma Allergy 2008; 1: 11–8.
22. Newman SP, Brown J, Steed KP et al. Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines: comparison of RESPIMAT with conventional metered-dose inhalers with and without spacer devices. Chest 1998; 113 (4): 957–63.
23. Richards J, Hirst P, Pitcairn G et al. Deposition and pharmacokinetics of flunisolide delivered from pressurized inhalers containing non-CFC and CFC propellants. J Aerosol Med 2001; 14 (2): 197–208.
24. Newman S, Salmon A, Nave R, Drollmann A. High lung deposition of 99mTc-labeled ciclesonide administered via HFA-MDI to patients with asthma. Respir Med 2006; 100 (3): 375–84.
25. Rau JL. The Inhalation of Drugs: Advantages and Problems. Respir Care 2005; 50: 367–82.
26. Newman SP. How Well Do In Vitro Particle Size Measurements Predict Drug Delivery In Vivo? J Aerosol Med 1998; 11 (s1): S-97–S-104.
27. Kelly HW. Comparison of inhaled corticosteroids: an update. Ann Pharmacother 2009; 43 (3): 519–27.
28. Usmani OS. Treating the small airways. Respiration 2012; 84 (6): 441–53.
29. Weibel ER. Design of airways and blood vessels considered as branching trees. The Lung: Sci Foundations 1991; 1: p. 711–20 (Eds-in-Chief, Crystal RG and West JB).
30. Stein SW. Estimating the number of droplets and drug particles emitted from MDIs. AAPS Pharm Sci Tech 2008; 9 (1): 112–5.
31. Steckel H, Wehle S. A novel formulation technique for metered dose inhaler (MDI) suspensions. Int J Pharm 2004; 284 (1–2): 75–82.
32. Newmana S, Salmona A, Naveb R, Drollmannb A. High lung deposition of 99mTc-labeled ciclesonide administered via HFA-MDI to patients with asthma. Respir Med 2006; 100: 375–84.
33. Thorsson L, Kenyon C, Newman SP, Borgström L. Lung deposition of budesonide in asthmatics: a comparison of different formulations. Int J Pharmaceut 1998; 168: 119–27.
34. Cohen J, Douma WR, ten Hacken NH et al. Ciclesonide improves measures of small airway involvement in asthma. Eur Respir J 2008; 31 (6): 1213–20.
35. Hoshino M. Comparison of Effectiveness in Ciclesonide and Fluticasone Propionate on Small Airway Function in Mild Asthma. Allergol Int 2010; 59: 59–66.
36. Pedersen S. First European ADMIT Conference on Inhalation Devices in Asthma and COPD 2008.
37. Leach CL, Davidson PJ, Hasselquist BE, Boudreau RJ. Influence of particle size and patient dosing technique on lung deposition of HFA-beclomethasone from a metered dose inhaler. J Aerosol Med 2005; 18: 379–85.
38. Leach CL, Davidson PJ, Hasselquist E, Boudreau RJ. Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone. Chest 2002; 122: 510–6.
39. Derendorf H. Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety. Respir Med 1997; 91 (Suppl. A): 22–8.
40. Brutsche MH, Brutsche IC, Munawar M et al. Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study. Lancet 2000; 356: 556–61.
41. Lipworth BJ. New perspectives on inhaled drug delivery and systemic bioactivity. Thorax 1995; 50 (2): 105–10.
42. Seale JP, Harrison LI. Effect of changing the fine particle mass of inhaled beclomethasone dipropionate on intrapulmonary deposition and pharmacokinetics. Respir Med 1998; 92 (Suppl. A): 9–15.
43. Holz O, Zühlke I, Einhaus M et al. Direct measurement of BDP and 17-BMP in bronchial and peripheral lung tissue after inhalation of HFA- vs CFC-driven aerosols. Pulm Pharmacol Ther 2004; 17 (4): 233–8.
44. Newman S, Salmon A, Nave R, Drollmann A. High lung deposition of 99mTc-labeled ciclesonide administered via HFA-MDI to patients with asthma. Respir Med 2006; 100 (3): 375–84.
45. Nave R, Meyer W, Fuhst R, Zech K. Formation of fatty acid conjugates of ciclesonide active metabolite in the rat lung after 4-week inhalation of ciclesonide. Pulm Pharmacol Ther 2005; 18 (6): 390–6.
46. Nave R, McCracken N. Metabolism of ciclesonide in the upper and lower airways: review of available data. J Asthma Allergy 2008; 1: 11–8.
47. Nave R, McCracken N. Metabolism of ciclesonide in the upper and lower airways: review of available data. J Asthma Allergy. 2008; 1: 11–8.
48. Johnson M, Dalby R, Byron P et al. Fluticasone propionate: pharmacokinetic and pharmacodynamic implications of different aerosol delivery systems. Buffalo Grove, IL: Interpharm Press. Respir Drug Delivery VI. 1998; p. 61–70.
49. Pitcairn G, Reader S, Pavia D, Newman S. Deposition of corticosteroid aerosol in the human lung by Respimat Soft Mist inhaler compared to deposition by metered dose inhaler or by Turbuhaler dry powder inhaler. J Aerosol Med 2005; 18 (3): 264–72.
50. Доклад рабочей группы GINA (Global Initiative for Asthma), пересмотр 2012 г. // www.ginasthma.org
51. ATC/DDD Index 2013 WHO Collaborating Centre for Drug Statistics Methodology; http://www.whocc.no/atc_ddd_index/

В.В.Архипов1, Н.В.Матвеев2

1. ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России;
2. ГБОУ ВПО Российский национальный исследовательский медицинский университет им. Н.И.Пирогова Минздрава России